NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.93 +0.08 (+0.54 %)
(As of 02/20/2019 10:02 AM ET)
Previous Close$14.85
Today's Range$14.93 - $14.93
52-Week Range$8.10 - $19.58
Volume205 shs
Average Volume32,965 shs
Market Capitalization$473.58 million
P/E Ratio-1.88
Dividend YieldN/A
Beta-0.05
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.47 per share

Profitability

Net Income$-115,450,000.00

Miscellaneous

Employees30
Market Cap$473.58 million
OptionableNot Optionable

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) announced its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04. View Clementia Pharmaceuticals' Earnings History.

When is Clementia Pharmaceuticals' next earnings date?

Clementia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Clementia Pharmaceuticals.

What price target have analysts set for CMTA?

5 Wall Street analysts have issued 12 month price objectives for Clementia Pharmaceuticals' shares. Their forecasts range from $16.00 to $26.00. On average, they anticipate Clementia Pharmaceuticals' share price to reach $23.00 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price. View Analyst Price Targets for Clementia Pharmaceuticals.

What is the consensus analysts' recommendation for Clementia Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clementia Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clementia Pharmaceuticals.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

Press coverage about CMTA stock has trended somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clementia Pharmaceuticals earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Are investors shorting Clementia Pharmaceuticals?

Clementia Pharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 271,219 shares, a decrease of 84.5% from the December 31st total of 1,745,347 shares. Based on an average daily volume of 45,715 shares, the short-interest ratio is currently 5.9 days. Currently, 1.0% of the company's stock are sold short. View Clementia Pharmaceuticals' Current Options Chain.

Who are some of Clementia Pharmaceuticals' key competitors?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:
  • Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 52)
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 62)
  • Mr. Jeffery Packman, Chief Devel. Officer (Age 52)
  • Mr. Steve Forte, CFO & Corp. Sec.
  • Mr. Joseph Andrew Walewicz, Exec. VP of Bus. & Corp. Devel. (Age 50)

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an initial public offering on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and Leerink Partners served as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

Who are Clementia Pharmaceuticals' major shareholders?

Clementia Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.54%), Perceptive Advisors LLC (4.73%), Artal Group S.A. (2.68%), Partner Fund Management L.P. (2.68%), Fosun International Ltd (0.74%) and Birchview Capital LP (0.70%).

Which major investors are selling Clementia Pharmaceuticals stock?

CMTA stock was sold by a variety of institutional investors in the last quarter, including Weiss Multi Strategy Advisers LLC and United Services Automobile Association.

Which major investors are buying Clementia Pharmaceuticals stock?

CMTA stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, NEA Management Company LLC, Partner Fund Management L.P., Fosun International Ltd, Artal Group S.A., Birchview Capital LP, UBS Oconnor LLC and UBS Oconnor LLC.

How do I buy shares of Clementia Pharmaceuticals?

Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $14.93.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $473.58 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.

What is Clementia Pharmaceuticals' official website?

The official website for Clementia Pharmaceuticals is http://www.clementiapharma.com.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]


MarketBeat Community Rating for Clementia Pharmaceuticals (NASDAQ CMTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel